公开(公告)号：US20190144501A1

公开(公告)日：2019-05-16

申请号：US16099974

申请日：2017-05-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA REC HERCHE MÉDICALE) ,  UNIVERSITE PARIS DESCARTES ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7

发明人： Santos A. Susin ,  Philippe Karoyan ,  Hélène Merle-Beral

IPC分类号： C07K7/06 ,  A61P35/00

摘要： The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

公开(公告)号：US20190105369A1

公开(公告)日：2019-04-11

申请号：US16087223

申请日：2017-03-21

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  UNIVERSITE PARIS 13 - PARIS NORD

发明人： Giuseppina CALIGIURI ,  Jean-Baptiste MICHEL ,  Antonino NICOLETTI

IPC分类号： A61K38/17 ,  A61P9/10

摘要： Disclosed are CD31shed agonists for use in the prevention and/or treatment of reperfusion injury. These CD31shed agonists are peptides or peptidomimetics thereof that are able to restore CD31 signaling in cells bearing a truncated form of CD31 called CD31shed. The CD31shed agonists particularly protect from organ damages caused by reperfusion used to treat ischemia.

公开(公告)号：US20190022097A1

公开(公告)日：2019-01-24

申请号：US16055571

申请日：2018-08-06

申请人： URGO RECHERCHE INNOVATION ET DÉVELOPPEMENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ECOLE NORMALE SUPERIEURE

发明人： Claire Dugast-Darzacq ,  Maïté Noizet ,  Xavier Darzacq ,  Beatrice Spiluttini Hebert

IPC分类号： A61K31/519 ,  C12N15/113 ,  C07K14/47 ,  A61K45/06 ,  A61K9/00 ,  A61K31/197 ,  A61K31/506 ,  A61L15/16

摘要： The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

公开(公告)号：US10172921B2

公开(公告)日：2019-01-08

申请号：US15320827

申请日：2015-06-23

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT—PARIS 7 ,  ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS

发明人： Alain Couvineau ,  Thierry Voisin ,  Nassima Messal ,  Eric Ogier-Denis ,  Xavier Treton

IPC分类号： A61K38/00 ,  A61K38/22 ,  A61K45/06

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.

公开(公告)号：US10076517B2

公开(公告)日：2018-09-18

申请号：US15512872

申请日：2015-09-21

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT-PARIS 7 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： Sophie Lotersztajn ,  Aïda Habib

IPC分类号： A61K31/4015 ,  A61K31/4525 ,  A61K31/496 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4545

CPC分类号： A61K31/496 ,  A61K31/4015 ,  A61K31/4525 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4545

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.

公开(公告)号：US20180132787A1

公开(公告)日：2018-05-17

申请号：US15568593

申请日：2016-04-22

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (NSERM) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  UNIVERSITÉ DE VERSAILLES SAINT-QUENTIN-EN-YVELINES

发明人： Benjamin LEPORQ ,  Simon LAMBERT ,  Bernard VAN BEERS

IPC分类号： A61B5/00 ,  A61B5/055 ,  G01R33/48 ,  G01R33/50 ,  G01R33/56 ,  G01R33/561

CPC分类号： A61B5/4872 ,  A61B5/055 ,  A61B5/748 ,  A61B2576/00 ,  G01R33/243 ,  G01R33/4828 ,  G01R33/50 ,  G01R33/5608 ,  G01R33/5615 ,  G01R33/5616 ,  G01R33/5618

摘要： A method for post-processing images of a region of interest in a subject, the images being acquired with a magnetic resonance imaging technique, the method for post-processing comprising at least the step of: unwrapping the phase of each image, extracting a real signal over echo time for at least one pixel of the unwrapped images, and calculating fat characterization parameters by using a fitting technique applied on a model, the model being a function which associates to a plurality of parameters each extracted real signal, the plurality of parameters comprising at least two fat characterization parameters and at least one parameter obtained by a measurement, the fitting technique being a non-linear least-square fitting technique using pseudo-random initial conditions.

公开(公告)号：US20230330062A1

公开(公告)日：2023-10-19

申请号：US18068682

申请日：2022-12-20

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7

发明人： Nicolas CHARLES ,  Christophe PELLEFIGUES

IPC分类号： A61K31/403

CPC分类号： A61K31/403 ,  A61K2300/00

摘要： The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
Figure: none

公开(公告)号：US20220002668A1

公开(公告)日：2022-01-06

申请号：US17291667

申请日：2019-11-28

申请人： Assistance Publique - Hôpitaux de Paris ,  Université Paris 5 René Descartes ,  Université Paris Diderot - Paris 7 ,  Université Paris Est - Créteil Val de Marne

发明人： Benjamin FOURNIER ,  Bruno GOGLY ,  Catherine MARCHAND-LEROUX ,  Ali NASSIF ,  Ihsène TAÏHI

IPC分类号： C12N5/079 ,  A61K35/30

摘要： This invention concerns a new method for differentiating oral neuroectodermal stem cells (CSO-NE), in particular human gingival neuroectodermal stem cells (CSGh), into oligodendrocytes (OL), and their use in the repair of the nervous system, in particular of head injuries.

公开(公告)号：US20210403869A1

公开(公告)日：2021-12-30

申请号：US17291661

申请日：2019-11-28

申请人： Assistance Publique - Hôpitaux de Paris ,  Université Paris 5 René Descartes ,  Université Paris Diderot - Paris 7 ,  Université Paris Est - Créteil Val de Marne

发明人： Benjamin FOURNIER ,  Bruno GOGLY ,  Ali NASSIF ,  Ihsène TAÏHI ,  François FERRE

IPC分类号： C12N5/077 ,  C12N5/071 ,  A61K35/32

摘要： The present invention concerns a method for inducing differentiation of neuroectodermal oral stem cells, in particular from FCS osteogenic medium PL osteogenic medium gingival tissue (GSCs), into osteoblasts by culturing them in an optimal serum-free medium supplemented by necessary components such as platelet lysate, growth hormone, heparin, and/or growth factors. The invention method provides osteoblasts for cell therapy, particularly for the restoration of bone defects in maxillary bones.

公开(公告)号：US20210403573A1

公开(公告)日：2021-12-30

申请号：US16625381

申请日：2017-06-22

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÈ PARIS DESCARTES ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS

发明人： Sophie LOTERSZTAJN ,  JingHong WAN ,  Valérie PARADIS ,  Agnès LEHUEN ,  Pushpa HEGDE ,  Emmanuel WEISS

IPC分类号： C07K16/28 ,  A61P1/16 ,  A61K31/519 ,  A61K31/60 ,  A61K31/11

摘要： Persistent inflammation is a driving force of fibrosis progression. Mucosal-Associated Invariant T (MAIT) cells are non-conventional T cells that display altered functions during chronic inflammatory diseases. Here, the inventors report a loss of circulating MAIT cells in cirrhotic patients and their hepatic accumulation in an activated phenotype within the fibrotic septa. Using two models of chronic liver injury, the inventors demonstrate that mice enriched in MAIT cells (Vα19TCRTg) show exacerbated liver fibrosis and higher number of hepatic fibrogenic cells than wild type counterparts, whereas MAIT cell-deficient mice (MR1−/−mice) are resistant. The results highlight the profibrogenic functions of MAIT cells and suggest that 1 targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury. Accordingly, the present invention relates to a method of treating fibrosis in a patient in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of inhibiting the activation of MAIT cells.